Have a personal or library account? Click to login
ELABELA as a Marker of Gestational Complications – A Review Cover

ELABELA as a Marker of Gestational Complications – A Review

By: Rafal Sibiak  
Open Access
|Jul 2022

References

  1. 1. Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318; DOI:10.1016/j.mce.2009.11.011.
  2. 2. Mancuso P. The role of adipokines in chronic inflammation. ImmunoTar-gets Ther. 2016;5; DOI:10.2147/ITT.S73223.
  3. 3. Frühbeck G, Catalán V, Rodrí guez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018;7; DOI:10.1080/21623945.2017.1402151.
  4. 4. Satoh N, Naruse M, Usui T, Tagami T, Suganami T, Yamada K, Kuzuya H, Shimatsu A, Ogawa Y. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care. 2004;27; DOI:10.2337/diacare.27.10.2488.
  5. 5. Gutaj P, Sibiak R, Jankowski M, Awdi K, Bryl R, Mozdziak P, Kempisty B, Wender-Ozegowska E. The Role of the Adipokines in the Most Common Gestational Complications. Int J Mol Sci. 2020;21:9408; DOI:10.3390/ijms21249408.
  6. 6. Inuzuka H, Nishizawa H, Inagaki A, Suzuki M, Ota S, Miyamura H, Miyazaki J, Sekiya T, Kurahashi H, Udagawa Y. Decreased expression of apelin in placentas from severe pre-eclampsia patients. Hypertens Pregnancy. 2013;32; DOI:10.3109/10641955.2013.813535.
  7. 7. Couvineau P, Llorens-Cortes C, Iturrioz X. Elabela/Toddler and apelin bind differently to the apelin receptor. FASEB J. 2020;34:7989–8000; DOI:10.1096/fj.201903029R.
  8. 8. Ho L, Van Dijk M, Chye STJ, Messerschmidt DM, Chng SC, Ong S, Yi LK, Boussata S, Goh GHY, Afink GB, Lim CY, Dunn NR, Solter D, Knowles BB, Reversade B. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice. Science (80-). 2017;357; DOI:10.1126/science.aam6607.
  9. 9. Zhou Q, Zhang K, Guo Y, Chen L, Li L. Elabela-APJ axis contributes to embryonic development and prevents pre-eclampsia in pregnancy. Acta Biochim Biophys Sin (Shanghai). 2018;50:319–21; DOI:10.1093/abbs/gmx143.
  10. 10. Hassan SS, Gomez-Lopez N. Reducing maternal mortality: can elabela help in this fight? Lancet. 2019;394:8–9; DOI:10.1016/S0140-6736(19)30543-4.
  11. 11. Ma J, Hu H, Lin M, Chen L, Liu M, Li H, Quan S. ELABELA alleviates syncytiotrophoblast hypoxia/reoxygenation injury and preeclampsia-like symptoms in mice by reducing apoptosis. Placenta. 2021;106:30–9; DOI:10.1016/j.placenta.2021.02.002.33610935
  12. 12. Georgiadou D, Boussata S, Ranzijn WHM, Root LEA, Hillenius S, bij de Weg JM, Abheiden CNH, de Boer MA, de Vries JIP, Vrijkotte TGM, Lam-balk CB, Kuijper EAM, Afink GB, van Dijk M. Peptide hormone ELABELA enhances extravillous trophoblast differentiation, but placenta is not the major source of circulating ELABELA in pregnancy. Sci Rep. 2019;9; DOI:10.1038/s41598-019-55650-5.691103931836787
  13. 13. Zhou L, Sun H, Cheng R, Fan X, Lai S, Deng C. ELABELA, as a potential diagnostic biomarker of preeclampsia, regulates abnormally shallow placentation via APJ. Am J Physiol Metab. 2019;316:E773–81; DOI:10.1152/ajpendo.00383.2018.30860880
  14. 14. Wang L, Zhang Y, Qu H, Xu F, Hu H, Zhang Q, Ye Y. Reduced ELABELA expression attenuates trophoblast invasion through the PI3K/AKT/mTOR pathway in early onset preeclampsia. Placenta. 2019;87:38–45; DOI:10.1016/j.placenta.2019.08.077.31546152
  15. 15. Wang X, Liang G, Guo Q, Cai W, Zhang X, Ni J, Tao Y, Niu X, Chen S. ELABELA improves endothelial cell function via the ELA–APJ axis by activating the PI3K/Akt signalling pathway in HUVECs and EA.hy926 cells. Clin Exp Pharmacol Physiol. 2020:1440-1681.13382; DOI:10.1111/1440-1681.13382.32687618
  16. 16. Huang R, Zhu J, Zhang L, Hua X, Ye W, Chen C, Sun K, Wang W, Feng L, Zhang J. Is ELABELA a reliable biomarker for hypertensive disorders of pregnancy? Pregnancy Hypertens. 2019;17:226–32; DOI:10.1016/j.preghy.2019.06.007.700177131487645
  17. 17. Hao S, You J, Chen L, Zhao H, Huang Y, Zheng L, Tian L, Maric I, Liu X, Li T, Bianco YK, Winn VD, Aghaeepour N, Gaudilliere B, Angst MS, Zhou X, Li Y-M, Mo L, Wong RJ, Shaw GM, Stevenson DK, Cohen HJ, Mcelhinney DB, Sylvester KG, Ling XB. Changes in pregnancy-related serum biomarkers early in gestation are associated with later development of preeclampsia. PLoS One. 2020;15:e0230000; DOI:10.1371/journal.pone.0230000.705375332126118
  18. 18. Ozgen G, Aydin GA, Ayvaci H. Predictive Role of First-trimester ELABELA Levels for Late-onset Preeclampsia. J Coll Physicians Surg Pakistan. 2021;31:916–20; DOI:10.29271/jcpsp.2021.08.916.34320707
  19. 19. Ma S, Guo C, Zhang J, Long S, Tan H, You Y, Chase PB. Association between ELABELA Serum Concentrations in First Trimester and Pregnancy-Induced Hypertension. Biomed Res Int. 2020;2020:1–5; DOI:10.1155/2020/2051701.753910133062670
  20. 20. Pritchard N, Kaitu’u-Lino TJ, Gong S, Dopierala J, Smith GCS, Charnock-Jones DS, Tong S. ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia. Am J Pathol. 2018;188; DOI:10.1016/j.ajpath.2018.04.008.606399629803833
  21. 21. Panaitescu B, Romero R, Gomez-Lopez N, Pacora P, Erez O, Vadillo-Ortega F, Yeo L, Hassan SS, Hsu C-D. ELABELA plasma concentrations are increased in women with late-onset preeclampsia. J Matern Neonatal Med. 2020;33:5–15; DOI:10.1080/14767058.2018.1484089.634267529890874
  22. 22. Villie P, Lefevre G, Arrestier R, Rousseau A, Berkane N, Hertig A. ELABELA concentration is not decreased in maternal plasma before the onset of preeclampsia. Am J Obstet Gynecol. 2019;220:284–5; DOI:10.1016/j.ajog.2018.12.020.30576665
  23. 23. Para R, Romero R, Gomez-Lopez N, Tarca AL, Panaitescu B, Done B, Hsu R, Pacora P, Hsu CD. Maternal circulating concentrations of soluble Fas and Elabela in early- and late-onset preeclampsia. J Matern Neonatal Med. 2020; DOI:10.1080/14767058.2020.1716720.32008387
  24. 24. Deniz R, Baykus Y, Ustebay S, Ugur K, Yavuzkir Ş, Aydin S. Evaluation of elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns. J Obstet Gynaecol (Lahore). 2019;39; DOI:10.1080/01443615.2019.1572727.31064239
  25. 25. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care. 2010;33:676–82; DOI:10.2337/dc09-1848.282753020190296
  26. 26. Guo YY, Li T, Liu H, Tang L, Li YC, Hu HT, Su YF, Lin Y, Wang YY, Li C, Huang HF, Jin L, Liu XM. Circulating levels of Elabela and Apelin in the second and third trimesters of pregnancies with gestational diabetes mellitus. Gynecol Endocrinol. 2020; DOI:10.1080/09513590.2020.1739264.32208782
  27. 27. Karagoz ZK, Aydin S, Ugur K, Tigli A, Deniz R, Baykus Y, Sahin I, Yalcin MH, Yavuz A, Aksoy A, Aydin S. Molecular communication between Apelin-13, Apelin-36, Elabela, and nitric oxide in gestational diabetes mellitus. Eur Rev Med Pharmacol Sci. 2022;26:3289–300; DOI:10.26355/eurrev_202205_28748.35587081
  28. 28. Behram M, Oğlak SC, Dağ İ. Circulating levels of Elabela in pregnant women complicated with intrauterine growth restriction. J Gynecol Obstet Hum Reprod. 2021;50:102127; DOI:10.1016/j.jogoh.2021.102127.33781971
  29. 29. Yener G, Kavak SB, Gul Y, Celik Kavak E, Gulcu Bulmus F, Sanli C, Batmaz I, Bulu G. Elabela levels in pregnancies with intrauterine growth retardation. Ginekol Pol. 2022; DOI:10.5603/GP.a2021.0246.35315019
Language: English
Page range: 43 - 48
Submitted on: Apr 2, 2022
|
Accepted on: May 26, 2022
|
Published on: Jul 9, 2022
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Rafal Sibiak, published by Foundation for Cell Biology and Molecular Biology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.